Trials / Recruiting
RecruitingNCT06285318
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 900 (estimated)
- Sponsor
- Janssen-Cilag Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Teclistamab | No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into CRF. |
| OTHER | Talquetamab | No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into CRF. |
Timeline
- Start date
- 2023-12-18
- Primary completion
- 2026-06-30
- Completion
- 2026-07-31
- First posted
- 2024-02-29
- Last updated
- 2026-04-13
Locations
68 sites across 11 countries: Denmark, France, Germany, Greece, Ireland, Israel, Italy, Norway, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT06285318. Inclusion in this directory is not an endorsement.